In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a price target of $181.00. The company's shares closed last Tuesday at $179.90, close to its 52-week high of $184.20. According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.2% and a 47.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Arcutis Biotherapeutics, and Revolution Medicines. Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $187.82, representing a 4.8% upside.
https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-hold-on-johnson-johnson-jnj?utm_source=advfn.com&utm_medium=referral